Acute Kidney Injury, Hemodialysis
Conditions
Keywords
Activin A, Nostrin, Angiopoetin-2, Acute kidney injury, Hemodialysis
Brief summary
The aim of this study was to evaluate the role of Activin A, Nostrin, and Angiopoetin-2 levels in predicting the prognosis of renal function and in-hospital and 6-month mortality in patients undergoing emergency hemodialysis treatment for acute kidney injury. The main questions it aims to answer are: Acute renal injury is a clinical entity with very important consequences. Mortality and morbidity are high in patients requiring hemodialysis. This study aims to evaluate the predictive effects of certain biomarkers on outcomes such as short- and long-term monitoring of renal function, weaning or continuation of hemodialysis, in-hospital and 6-month mortality in these patients. In patients with an indication for emergency hemodialysis, the following levels will be measured before hemodialysis: * Serum Activin A, * Serum Nostrin, * Serum Angiopoetin-2
Detailed description
In this single-center study, the investigators evaluated patients diagnosed with acute kidney injury (AKI) who underwent emergency hemodialysis. AKI has a high mortality rate and can be accompanied by many complications. Progression to chronic kidney disease is one of the most important of these complications. Identifying prognostic determinants in patients receiving hemodialysis treatment due to AKI can provide significant benefits for clinical practice. In this study, the investigators aimed to determine the prognosis in this patient group using some vascular-endothelial markers. The investigators collected serum samples before hemodialysis from AKI patients indicated for hemodialysis and measured the levels of Activin A, Nostrin, and Angiopoetin-2. The investigators aimed to evaluate the relationship between these levels and parameters such as in-hospital mortality, 6-month mortality, and weaning from hemodialysis after 6 months or hemodialysis dependence.
Interventions
DIAGNOSTIC_TESTSerum samples before hemodialysis.
Except from taking a venous blood sample there are no interventions.
Sponsors
Muğla Sıtkı Koçman University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SCREENING
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients 18 years and older of age requiring hemodialysis for acute kidney injury
Exclusion criteria
* Patients under 18 years of age * Patients under chronic renal replacement therapy * Patients with a history of renal transplantation
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Correlation of serum nostrin, activin A, angiopoetin-2 levels and in-hospital clinical results and outcomes (mortality, weaning from HD) | From the day of the first hemodialysis session until in-hospital death or discharge. (maximum up to 100 days) | Up to 3 months were sufficient for patient recruitment for the study. After patient recruitment was completed, the investigators followed the patients during their in-hospital days monitoring their need for hemodialysis and survival/death status. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| All cause mortality and need for hemodialysis or weaning from hemodialysis | 180 days after the initiation of first hemodialysis session | Patients who were discharged from the hospital after the initiation of hemodialysis were followed up for 180 days in terms of discontinuing or continuing hemodialysis treatment and survival/death status. |
Countries
Turkey (Türkiye)
Contacts
PRINCIPAL_INVESTIGATORAlper Alp, Assoc Prof,MD
Muğla Sıtkı Koçman University
Outcome results
None listed